Pharma Q2fy23 Preview
The Pharma universe under our coverage could report aggregate Revenue/EBITDA/PAT growth of 5.6%/-4.8%/-2.2% YoY. Currency (Rs) has depreciated by 5.0%
263 Views
Pharmaceutical Sector: Sequentially Flattish Quarter Expected
4QFY22 is expected to be a flattish quarter for most Pharma companies in our coverage universe. We expect a few companies to benefit from the US...
473 Views
Gland Pharma Ltd - Uptick in Margins; Strong Launch Momentum
Stable Core and Cenexi Turnaround Drive Revenue Growth: Gland Pharma reported consolidated revenue of Rs 1,506 Cr in Q1FY26, marking a 7.4% YoY...
218 Views
Gland Pharma Ltd - Base Business Facing Challenges; New Launches Offer Optimism
Encouraging Financial Performance: GLAND’s base business (Ex-Cenexi) registered a 12.3% YoY revenue degrowth due to price erosion.
215 Views
Gland Pharma - New Launches and Higher Milestone Income Drive Margins
While revenue came in line, product mix and a higher share of milestone income led to better-than-expected margins in the base business.
270 Views